A year after raising $66m in a series B, the Zug, Switzerland-headquartered start-up biotech, Pharvaris B.V. has just raised a hefty $80m in a series C round, with its lead product expected to enter Phase II clinical trials in 2021.
Pharvaris is developing an orally administered bradykinin B2 receptor antagonist, PHA121, for the genetic disorder hereditary angioedema (HAE), a market...